Translations:Anti-obesity medication/16/en
Jump to navigation
Jump to search
As of 2022, no medication has been discovered that would equal the effectiveness of bariatric surgery for long-term weight loss and improved health outcomes.
| Medication Name | Trade name(s) | Mechanism of action | Current FDA Status | placebo-adjusted percent bodyweight lost (highest dose studied) |
|---|---|---|---|---|
| Semaglutide | Wegovy | GLP-1 receptor agonist | Approved for weight management (chronic) | 12% |
| Phentermine/topiramate | Qsymia | Phentermine is a substituted amphetamine and topiramate has an unknown mechanism of action | Approved for weight management (short-term) by the FDA but not the European Medicines Agency | 10% or 8.25 kilograms (18.2 lb) |
| Naltrexone/bupropion | Contrave | Approved for weight management (chronic) in the US and EU | 5 percent | |
| Liraglutide | Saxenda | GLP-1 receptor agonist | Approved for weight management (chronic) | 4 percent |
| Gelesis100 | Plenity | Oral hydrogel | FDA approved for weight management (chronic) but the American Gastroenterology Association recommends that its use be limited to clinical trials due to lack of evidence. | 2% |
| Orlistat | Xenical | Absorption inhibitor | Approved for weight management (chronic) | 3 kilograms (6.6 lb); percentage not provided |
| Phentermine | Substituted amphetamine | Approved for weight management (short-term) | 5 kilograms (11 lb) | |
| Methamphetamine | Desoxyn | Substituted amphetamine | Approved for weight management (short-term) | |
| Tirzepatide | Zepbound | Dual GLP-1 receptor agonist and GIP agonist | FDA approved for weight management (chronic); EMA approval for weight loss is pending | 10.91 kilograms (24.1 lb) |